首页 | 本学科首页   官方微博 | 高级检索  
     


First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study
Authors:W. Kreuz  C. Escuriola Ettingshausen  V. Vdovin  N. Zozulya  O. Plyushch  P. Svirin  T. Andreeva  E. Bubanská  M. Campos  M. Benedik‐Dolničar  V. Jiménez‐Yuste  L. Kitanovski  A. Klukowska  A. Momot  N. Osmulskaya  M. Prieto  S. Z. Šalek  F. Velasco  A. Pavlova  J. Oldenburg  S. Knaub  M. Jansen  L. Belyanskaya  O. Walter  the ObsITI study group  the ObsITI committee
Affiliation:1. HZRM, H?mophilie‐Zentrum Rhein Main Frankfurt‐M?rfelden, M?rfelden‐Walldorf, Germany;2. Izmaylovo Children's Hospital Haematological Centre, Moscow, Russia;3. The State Haematological Scientific Centre RAMS, Moscow, Russia;4. St. Petersburg State Healthcare Institution, St. Petersburg, Russia;5. Children Faculty Hospital with Policlinic, Banská Bystrica, Slovakia;6. Centro Hospitalar Porto, Hospital de Santo António, Porto, Portugal;7. Children's Hospital Oncology‐Hematology Unit, University Medical Center Ljubljana, Ljubljana, Slovenia;8. Hospital La Paz, Madrid, Spain;9. Medical Academy, Warsaw, Poland;10. Altai Hematological Center, Altai, Russia;11. State Healthcare Institution of Omsk Region, Omsk, Russia;12. Hospital General Yagüe, Castilla Leon, Spain;13. University Hospital REBRO, Zagreb, Croatia;14. Hospital Reina Sofía, Córdoba, Spain;15. Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany;16. Octapharma AG, Lachen, Switzerland;17. Octapharma Pharmazeutika Produktionsges.mbH, Vienna, Austria
Abstract:
Keywords:Bonn protocol  factor VIII inhibitors  factor VIII/von Willebrand factor concentrate  haemophilia A  immune tolerance induction  poor prognosis for immune tolerance induction
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号